Literature DB >> 10622545

Diagnostic and therapeutic process and prognosis in suspected lung cancer.

T Ringbaek1, S Borgeskov, P Lange, K Viskum.   

Abstract

Survival rates of patients with lung cancer are poor in Denmark and worse than in the other Nordic countries. The study focuses on the diagnostic process, the selection for operation, prognostic factors and outcome in lung cancer. The study comprised 467 consecutive patients with cancer-suspect lesions. In 40% of cases the diagnostic delay exceeded 30 days. Fibreoptic bronchoscopy and fine-needle biopsy (FNB) were the most important diagnostic tests, with approximately 90% accuracy in central and peripheral lesions. FNB of peripheral lesions diagnosed benign histology or small cell lung cancer (SCLC) in 16 patients, and due to that procedure a thoracotomy was prevented. Surgery was performed on 83 (33%) of 252 patients with non-small cell lung cancer. Three-year survival was 37% in all surgically treated patients and 64% after radical operation; 59% of the patients with stage I tumours were alive after three years, but none with stage IV at diagnosis. Among patients operated on, preoperated forced expiratory volume (FEV1) was related to survival rate. Survival rates were higher in women than in men with or without surgery. Of 43 patients with SCLC, 32 received chemotherapy, and half of these were alive after one year. Conclusions from the study were that diagnosis should be speeded up and that diagnostic FNB of peripheral lesions is of value for preventing unnecessary operations. Standard registration of tumour, node, metastasis (TNM) classification, resection, FEV1 (% of predicted) and gender could increase the validity of international comparisons.

Entities:  

Mesh:

Year:  1999        PMID: 10622545     DOI: 10.1080/14017439950141399

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  3 in total

1.  Effect of delays on survival in patients with lung cancer.

Authors:  Francisco Javier González-Barcala; José María García-Prim; José Manuel Alvarez-Dobaño; Milagros Moldes-Rodríguez; María Teresa García-Sanz; Antonio Pose-Reino; Luis Valdés-Cuadrado
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

2.  Clinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  David E Ost; Sai-Ching Jim Yeung; Lynn T Tanoue; Michael K Gould
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

3.  Integrated analysis reveals five potential ceRNA biomarkers in human lung adenocarcinoma.

Authors:  Yu Liu; Deyao Xie; Zhifeng He; Liangcheng Zheng
Journal:  PeerJ       Date:  2019-04-29       Impact factor: 2.984

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.